Physician profile
Mark Haldeman
NPI 1164472833
$1,597.27
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $724.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $370.97 | 2019-2020 | |
| Novo Nordisk INC | $181.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $168.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.41 | 2019-2020 | |
| Lilly USA, LLC | $149.34 | 2019-2020 | |
| Amarin Pharma, INC. | $117.69 | 2019-2020 | |
| Amgen INC. | $97.06 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.74 | 2019 | |
| Astellas Pharma US INC | $41.96 | 2019 | |
| Glaxosmithkline, LLC. | $38.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.09 | 2019-2020 | |
| Valeritas, INC. | $25.90 | 2019 | |
| Sanofi Pasteur INC. | $16.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $14.99 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.42 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.85 | 2019 | |
| Circassia INC. | $11.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.20 | 2019 | |
| Pfizer INC. | $11.17 | 2019 | |
| Daiichi Sankyo INC. | $11.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Haldeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.